イムノアッセイの世界市場予測（2022年～2027年）

世界のイムノアッセイの市場規模は、2020年は288億1,500万米ドルで、予測期間中に6.31％のCAGRで成長し、2027年には442億2,200万米ドルに達すると予想されています。

当レポートでは、世界のイムノアッセイ市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および抑制要因、タイプ・治療領域・エンドユーザー・地域別の分析、および競合情勢などを提供しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 前提条件

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 業界における競合情勢
• 業界のバリューチェーン分析

第5章 世界のイムノアッセイ市場分析：タイプ別

• イントロダクション
• 放射免疫測定（RIA）
• 酵素免疫測定法または酵素結合免疫吸着測定法（ELISA）
• カウントイムノアッセイ（CIA）
• 蛍光免疫測定（FIA）
• 化学発光イムノアッセイ（CLIA）

第6章 世界のイムノアッセイ市場分析：治療領域別

• イントロダクション
• 感染症
• 骨代謝
• 免疫学
• 神経生物学
• その他

第7章 世界のイムノアッセイ市場分析：エンドユーザー別

• イントロダクション
• 病院とクリニック
• 診断
• 製薬およびバイオテクノロジー企業
• 研究＆学術ラボ

第8章 世界のイムノアッセイ市場分析：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • その他
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • その他
• アジア太平洋
  • 日本
  • 中国
  • インド
  • タイ
  • 台湾
  • インドネシア
  • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場の収益性
• 合併、買収、合意、およびコラボレーション
• ベンダー競争力マトリックス

第10章 企業プロファイル

• Fujirebio
• Quidel Corporation
• Roche Diagnostics
• Immunodiagnostic Systems
• Arbor Assays
• Omega Diagnostics Group PLC
• Beckman Coulter Inc.
• ImmunoReagents Inc.
• Abbott
• Mercodia AB

The global immunoassay market was valued at US$28.815 billion in 2020 and is expected to grow at a CAGR of 6.31% over the forecast period to reach a total market size of US$44.222 billion by 2027.

An immunoassay is a bioanalytical method that employs antigen-antibody affinity to identify and quantify molecules of interest in biological samples. Immunoassays are quick and accurate tests that may be performed in the lab to identify particular substances.

Increased R & D efforts, as well as an increase in disease diagnostics, cancer markers, cardiac analysis, therapeutic medication monitoring, and clinical research methods, are projected to fuel market growth. In hospitals and medical laboratories, immunoassays can be used to perform automated biochemical tests to identify the presence and concentration of certain chemicals in samples. The use of immunoassays in numerous bioanalytical applications such as medical diagnostics, environmental monitoring, biopharmaceutical analysis, and food testing is propelling the market's growth.

The key drivers driving market expansion are the escalation of occurrences and the prevalence of infectious illnesses. According to the World Health Organization (WHO), seven out of every hundred hospitalised patients in developed countries and ten in poor countries will contract at least one healthcare-related infection. As a result, the rising number of patients suffering from infectious illnesses is expected to result in a significant demand for immunoassay devices throughout the world.

However, inadequate reimbursement guidelines are anticipated to hinder the immunoassay market expansion.

North America is likely to lead the immunoassay market for a few more years. This can be attributed mostly to the soaring rates of chronic and infectious diseases and the expanding geriatric population, as well as the well-developed healthcare infrastructure of the region and the increasing penetration of medical technology. Six out of every ten Americans have at least one chronic condition, such as heart disease, stroke, cancer, or diabetes. Furthermore, increased R & D spending by government organisations and pharmaceutical companies for disorders and diseases such as chronic illnesses and diabetes are some of the key drivers driving the regional market.

Growth Factors

• Increase in infectious disease prevalence and disease diagnostic research:

Chronic conditions, including diabetes, cardiovascular disease, and cancer, are on the increase all across the globe. Infectious diseases such as SARS-CoV2 (COVID-19), Dengue, Hepatitis B and C, HIV, malaria, tuberculosis, and others are also on the rise. Immunoassay diagnosis has become an important component of many diseases' diagnostic protocols. Immunoassay technology advancements are providing faster results with greater effectiveness, detection limits, sensitivity, and cost-efficiency. The widespread use of quick tests and point-of-care testing for disease diagnosis and drug and alcohol addiction has fueled the worldwide immunoassay market expansion.

Restraints:

• Stringent regulatory requirements:

The licencing and marketing of immunoassay consumables and equipment has been subject to strict requirements by regulatory agencies in various countries. Furthermore, technological challenges faced by immunoassay kits and reagents, such as cross-reactivity of antibodies, limited detection limits of available antibodies, false negatives, and others, slow immunoassay market growth. The technicians encounter several design problems associated with immunoassays, such as misinterpretation of results. . Furthermore, a shortage of trained experts in the clinical diagnostics sector has created problems for several decades.

COVID-19's Impact on the Immunoassay Market:

The immunoassay product is essential in slowing the spread of COVID-19. In the absence of a vaccine or cure, the only effective way to prevent and manage virus outbreaks and their consequences is via diagnosis. Rapid testing has developed as an effective, quick, and simple molecular test for large-scale COVID-19 monitoring. Massive research, valuations, and approvals of several immunoassay consumables and analyzers have addressed the SARS-CoV2 detection problems. The usage of immunoassays such as chemiluminescence, enzyme-linked, lateral flow-based point of care testing, fast tests, and other technologies has increased. The market has been influenced by the demanding regulatory procedures for immunoassay product approval, as well as the technological challenges of immunoassay kits and reagents. Because of the widespread diagnosis of COVID-19, the immunoassay market in many countries has grown dramatically during the pandemic. Furthermore, the market is projected to rise further with the increase in the number of COVID-19 cases.

Key Developments

• The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) label for Quanterix Corporation's Simoa® SARS-CoV-2 N Protein Antigen Test to enable testing using a nasal swab and saliva samples, as well as asymptomatic serial testing, as of September 2021.
• BioMerieux SA announced in January 2020 that its molecular biology subsidiary, BioFire Diagnostics, has applied to the Food and Drug Administration for clearance of the BIOFIRE Blood Culture Identification 2 (BCID2) Panel. When compared to the previous BIOFIRE BCID Panel, the BIOFIRE BCID2 Panel includes numerous more pathogens, an enlarged list of antibiotic resistance genes, and several revised targets.
• Snibe Diagnostic announced in April 2021 that its Maglumi HIV Ab/Ag Combi CLIA kit, a fourth-generation chemiluminescence immunoassay that detects HIV-1 and HIV-2 antibodies as well as the HIV-1 p24 antigen, had received CE marking, allowing it to be sold in the European Union and other regions that accept the designation.

Segmentation:

• By Type

Radioimmunoassay (RIA)

Enzyme Immunoassays or Enzyme-linked immunosorbent assays (ELISA)

Counting Immunoassay (CIA)

Fluoroimmnoassay (FIA)

Chemiluminescence immunoassay (CLIA)

• By Therapeutic Area

Infectious Diseases

Bone Metabolism

Immunology

Neurobiology

Others

• By End-User

Hospitals & Clinics

Diagnostics

Pharmaceutical & Biotechnology Companies

Research & Academic Laboratories

• By Geography

North America

• United States
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• UK
• France
• Germany
• Italy
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Others

Asia Pacific

• Japan
• China
• India
• Thailand
• Taiwan
• Indonesia
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porters Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. The threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Global Immunoassay Market Analysis, By Type

• 5.1. Introduction
• 5.2. Radioimmunoassay (RIA)
• 5.3. Enzyme Immunoassays or Enzyme-linked immunosorbent assays (ELISA)
• 5.4. Counting Immunoassay (CIA)
• 5.5. Fluoroimmnoassay (FIA)
• 5.6. Chemiluminescence immunoassay (CLIA) 

6. Global Immunoassay Market Analysis, By Therapeutic Area

• 6.1. Introduction
• 6.2. Infectious Diseases
• 6.3. Bone Metabolism
• 6.4. Immunology
• 6.5. Neurobiology
• 6.6. Others

7. Global Immunoassay Market Analysis, By End-User

• 7.1. Introduction
• 7.2. Hospitals & Clinics
• 7.3. Diagnostics
• 7.4. Pharmaceutical & Biotechnology Companies
• 7.5. Research & Academic Laboratories

8. Global Immunoassay Market Analysis, By Geography 

• 8.1.  Introduction
• 8.2.  North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. UK
  • 8.4.2. France
  • 8.4.3. Germany
  • 8.4.4. Italy
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Thailand
  • 8.6.5. Taiwan
  • 8.6.6. Indonesia
  • 8.6.7. Others

9.  Competitive Environment and Analysis

• 9.1. Major Players and Strategy Analysis
• 9.2.  Emerging Players and Market Lucrativenessness
• 9.3.  Mergers, Acquisitions, Agreements, and Collaborations
• 9.4.  Vendor Competitiveness Matrix

10. Company Profiles

• 10.1. Fujirebio
• 10.2. Quidel Corporation
• 10.3. Roche Diagnostics
• 10.4. Immunodiagnostic Systems
• 10.5. Arbor Assays
• 10.6. Omega Diagnostics Group PLC
• 10.7. Beckman Coulter Inc.
• 10.8. ImmunoReagents Inc.
• 10.9. Abbott
• 10.10. Mercodia AB